Related Experiment Video
Updated: Jul 20, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles
Zhongtang Yu1,2,3, Xiaoqiang He1,2,3, Ruiliu Wang1,2,3
1International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development (MOE), Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China.
Abstract:
Owing to their remarkable pharmaceutical properties compared to those of noncovalent inhibitors, the development of targeted covalent inhibitors (TCIs) has emerged as a powerful method for cancer treatment. The K-Ras mutant, which is prevalent in multiple cancers, has been confirmed to be a crucial drug target in the treatment of various malignancies. However, although the K-Ras(G12D) mutation is present in up to 33% of K-Ras mutations, no covalent inhibitors targeting K-Ras(G12D) have been developed to date. The relatively weak nucleophilicity of the acquired aspartic acid (12D) residue in K-Ras may be the reason for this. Herein, we present the first compound capable of covalently engaging both K-Ras(G12D) and K-Ras(G12C) mutants. Proteome profiling revealed that this compound effectively conjugates with G12C and G12D residues, modulating the protein functions in situ. These findings offer a unique pathway for the development of novel dual covalent inhibitors.
Insights
Researchers developed the first targeted covalent inhibitors (TCIs) for K-Ras(G12D) and K-Ras(G12C) cancer mutations. This breakthrough enables new dual covalent inhibitor development for difficult-to-treat cancers.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Targeted covalent inhibitors (TCIs) offer advantages over noncovalent inhibitors in cancer therapy.
- K-Ras mutations are key targets in various cancers, with K-Ras(G12D) accounting for a significant portion.
- Existing covalent inhibitors do not target the K-Ras(G12D) mutation due to the residue's low nucleophilicity.
Purpose of the Study:
- To develop the first compound capable of covalently inhibiting both K-Ras(G12D) and K-Ras(G12C) mutants.
- To address the unmet need for covalent inhibitors targeting the K-Ras(G12D) mutation.
Main Methods:
- Development of a novel covalent inhibitor.
- Proteome profiling to assess compound conjugation and target engagement.
- In situ functional modulation studies.
Main Results:
- The novel compound successfully engages and covalently binds to both K-Ras(G12D) and K-Ras(G12C) mutants.
- Proteome profiling confirmed effective conjugation with the target G12C and G12D residues.
- The compound modulates protein functions in situ.
Conclusions:
- This study presents the first dual covalent inhibitor for K-Ras(G12D) and K-Ras(G12C).
- The findings provide a novel strategy for developing targeted covalent inhibitors against challenging K-Ras mutations.
- This opens new therapeutic avenues for cancers driven by these specific K-Ras mutations.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
Nitrosation of Enols
Regioselectivity of Electrophilic Additions-Peroxide Effect
Oxidation of Alkenes: Syn Dihydroxylation with Osmium Tetraoxide
α-Alkylation of Ketones via Enolate Ions
Keto–Enol Tautomerism: Mechanism

